No Data
No Data
No Data
No Data
No Data
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
Yahoo FinanceApr 22 11:53 ET
Don't Ignore The Insider Selling In Immunovant
We wouldn't blame Immunovant, Inc. (NASDAQ:IMVT) shareholders if they were a little worried about the fact that Peter Salzmann, the CEO & Director recently netted about US$990k selling shares at an av
Simply Wall StApr 22 06:00 ET
Buy Rating Affirmed for Immunovant on Strong Drug Development Prospects and Efficacy Confidence
TipRanksApr 22 05:55 ET
Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing
Peter Salzmann, Director, Chief Executive Officer, on April 17, 2024, sold 34,079 shares in Immunovant (IMVT) for $990,269. Following the Form 4 filing with the SEC, Salzmann has control over a total
MT NewswiresApr 19 18:01 ET
What Makes Immunovant (IMVT) a New Buy Stock
Yahoo FinanceApr 17 12:00 ET
Immunovant Initiated at Outperform by Oppenheimer
Immunovant Initiated at Outperform by Oppenheimer
Dow JonesMar 28 06:59 ET
No Data
No Data